

**Head Office** 

Mail: P.O. Box CT 2783, Cantonments-Accra, Ghana

(+233)-302-233200/235100

(+233)-551-112223/4/5 (Hotline)

Email: fda@fda.gov.gh

Digital Address: GA-237-7316

Type of Communication: Identification Number:

Safety Monitoring (Vaccines) FDA/CSD/CPE/PRS/21/0014

For Immediate Release:

28th July, 2021

## FDA APPROVES TWO (2) MORE COVID-19 VACCINES FOR USE IN GHANA

The Food and Drugs Authority (FDA) would want to bring to the attention of the general public that it has approved two (2) more COVID-19 vaccines for importation, distribution and use in Ghana. The two new vaccines are **Moderna** (Spikevax) and **Pfizer-BioNtech** (Comirnaty) bringing the total number of approved COVID-19 vaccines for use in Ghana to five (5) and are as follows:

- Sputnik V
- Covishield<sup>TM</sup>
- Covid-19 Vaccine Jassen
- Moderna (Spikevax)
- Pfizer-BioNtech (Comirnaty)

The FDA continues to use the Emergency Use Authorization (EUA) pathway, which is the accepted procedure for all national regulatory authorities globally, in order to ensure timely access to quality and safe medical products including vaccines during this pandemic.

The Authority therefore wishes to assure the public that all the approved COVID-19 vaccines have been subjected to rigorous safety parameters and therefore the public are to receive these vaccines without any reservations.

The FDA remains committed to safeguarding the health and safety of the public as mandated by the Public Health Act, 2012 (Act 851).

For further information regarding all FDA regulated products and this publication, please contact the FDA on any of the contacts below:

(

0551112224/5



0551112224



Fdaghana



fdaghana



fdaghana



fda@fda.gov.gh



DELESE A. A. DARKO (MRS)
CHIEF EXECUTIVE OFFICER

FDA...Your wellbeing, our priority.